Skip to main content

Table 1 Characteristics of study participants and population

From: A cross-sectional, facility based study of comorbid non-communicable diseases among adults living with HIV infection in Zimbabwe

Variable

Sample n = 1033 (100 %)

Population n = 9658 (100 %)

Male n = 316 (30.6 %)

Female n = 717 (69.4 %)

p value comparison between males and females

Sex (females), n (%)

717 (69.4 %)

6896 (71.4 %)

–

–

 

Age (years), median (IQR)

42 (36–50)

40 (37–53)

46 (39–53)

41 (35–48)

<0.001

Age category (years)

 18–≤35 (n,  %)

242 (23.5)

1565 (16.2)

51 (16.2)

191 (26.7)

<0.001

 35–≤45

406 (39.5)

3390 (35.1)

104 (33.1)

302 (42.4)

 45–≤55

247 (24.0)

3100 (32.1)

94 (29.9)

153 (21.4)

 >55*

134 (13.0)

1603 (16.6)

65 (20.7)

69 (9.7)

Baseline CD4 + cell count (cells/mL), median (IQR)

191 (104–310)

184 (85–279)

174 (95–269)

202 (108–312)

0.023

Baseline CD4+ cell count below 350 cells/mL number (%)

685 (84.6)

8654 (89.6)

212 (87.2)

473 (83.3)

0.153

Baseline WHO HIV clinical stage III–IV number (%)

451 (50.8)

5360 (55.5)

156 (55.5)

295 (48.8)

0.013

Duration since HIV seropositive state (years), median (IQR)

7.1 (5.4–9.2)

6.9 (5.0–9.1)

6.7 (5.1–9.3)

7.4 (5.5–9.2)

0.073

Duration of ART exposure (years), median (IQR)

5.3 (3.4–7.1)

5.3 (2.9–6.9)

5.2 (2.8–7.0)

5.4 (3.7–7.2)

0.234

Duration ART exposure (categorical) (years)

 <2, number (%):

182 (18.2)

1729 (17.9)

65 (21.1)

117 (16.8)

0.269

 2–5

262 (26.1)

2501 (25.9)

77 (25.0)

185 (26.6)

 >5

559 (55.7)

5302 (54.9)

166 (53.9)

393 (56.6)

ART regimen frequencies, (number,  %)

 PI-based

48 (4.7)

425 (4.4)

17 (5.4)

31 (4.3)

0.001

 D4T/3TC + EFV or NVP

624 (60.4)

5766 (59.7)

212 (67.1)

412 (57.5)

 TDF/3TC + EFV or NVP

246 (23.8)

2115 (21.9)

56 (16.1)

190 (26.5)

 AZT/3TC + EFV or NVP

115 (11.1)

1043 (10.8)

31 (9.8)

84 (11.7)